{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,12]],"date-time":"2025-06-12T00:40:10Z","timestamp":1749688810814,"version":"3.41.0"},"reference-count":65,"publisher":"Elsevier BV","issue":"1-2","license":[{"start":{"date-parts":[[2017,3,1]],"date-time":"2017-03-01T00:00:00Z","timestamp":1488326400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["bprch.com","clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Best Practice & Research Clinical Haematology"],"published-print":{"date-parts":[[2017,3]]},"DOI":"10.1016\/j.beha.2016.07.003","type":"journal-article","created":{"date-parts":[[2016,11,4]],"date-time":"2016-11-04T08:17:22Z","timestamp":1478247442000},"page":"149-157","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["Possible novel agents in marginal zone lymphoma"],"prefix":"10.1016","volume":"30","author":[{"given":"Pier Luigi","family":"Zinzani","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessandro","family":"Broccoli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.beha.2016.07.003_bib1","series-title":"Williams hematology","first-page":"1663","article-title":"Marginal zone B-cell lymphomas","author":"Zinzani","year":"2016"},{"key":"10.1016\/j.beha.2016.07.003_bib2","doi-asserted-by":"crossref","first-page":"2082","DOI":"10.1182\/blood-2015-12-624304","article-title":"The spectrum of MALT lymphoma at different sites: biological and therapeutic relevance","volume":"127","author":"Zucca","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.beha.2016.07.003_bib3","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1093\/annonc\/mds643","article-title":"ESMO Consensus conferences: guidelines on malignant lymphoma. Part 2: marginal zone lymphoma, mantle cell lymphoma, peripheral T-cell lymphoma","volume":"24","author":"Dreyling","year":"2013","journal-title":"Ann Oncol"},{"issue":"Suppl 6","key":"10.1016\/j.beha.2016.07.003_bib4","doi-asserted-by":"crossref","first-page":"vi144","DOI":"10.1093\/annonc\/mdt343","article-title":"Gastric marginal zone lymphoma of MALT type: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"24","author":"Zucca","year":"2013","journal-title":"Ann Oncol"},{"key":"10.1016\/j.beha.2016.07.003_bib5","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1093\/annonc\/mdn760","article-title":"Long-term outcome following Helicobacter pylori eradication in a retrospective study of 105 patients with localized gastric marginal zone B-cell lymphoma of MALT type","volume":"20","author":"Stathis","year":"2009","journal-title":"Ann Oncol"},{"key":"10.1016\/j.beha.2016.07.003_bib6","doi-asserted-by":"crossref","first-page":"2988","DOI":"10.1200\/JCO.2011.41.4466","article-title":"Chlamydophila psittaci eradication with doxycycline as first-line targeted therapy for ocular adnexae lymphoma: final results of an international phase II trial","volume":"30","author":"Ferreri","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.beha.2016.07.003_bib7","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1182\/blood-2013-02-486522","article-title":"Antibiotic therapy in nongastrointestinal MALT lymphoma: a review of the literature","volume":"122","author":"Kiesewetter","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.beha.2016.07.003_bib8","doi-asserted-by":"crossref","first-page":"e104","DOI":"10.1016\/S2352-3026(14)00021-0","article-title":"First-line response-adapted treatment with the combination of bendamustine and rituximab in patients with mucosa-associated lymphoid tissue lymphoma (MALT2008-01): a multicentre, single-arm, phase 2 trial","volume":"1","author":"Salar","year":"2014","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.beha.2016.07.003_bib9","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1002\/hon.2151","article-title":"Fludarabine-mitoxantrone-rituximab regimen in untreated indolent non-follicular non-Hodgkin\u2019s lymphoma: experience on 143 patients","volume":"33","author":"Zinzani","year":"2015","journal-title":"Hematol Oncol"},{"key":"10.1016\/j.beha.2016.07.003_bib10","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1200\/JCO.2011.40.6272","article-title":"Addition of rituximab to chlorambucil produces superior event-free survival in the treatment of patients with extranodal marginal-zone B-cell lymphoma: 5-year analysis of the IELSG-19 randomized study","volume":"31","author":"Zucca","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.beha.2016.07.003_bib11","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1111\/j.1365-2141.2007.06841.x","article-title":"Immunomodulatory drugs stimulate natural killer-cell function, alter cytokine production by dendritic cells, and inhibit angiogenesis enhancing the anti-tumour activity of rituximab in vivo","volume":"140","author":"Reddy","year":"2008","journal-title":"Br J Haematol"},{"key":"10.1016\/j.beha.2016.07.003_bib12","doi-asserted-by":"crossref","first-page":"4713","DOI":"10.1182\/blood-2009-04-217687","article-title":"Follicular lymphoma cells induce T-cell immunologic synapse dysfunction that can be repaired with lenalidomide: implications for the tumor microenvironment and immunotherapy","volume":"114","author":"Ramsay","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.beha.2016.07.003_bib13","doi-asserted-by":"crossref","first-page":"4650","DOI":"10.1158\/1078-0432.CCR-07-4405","article-title":"Lenalidomide enhances natural killer cell and monocyte-mediated antibody-dependent cellular cytotoxicity of rituximab-treated CD20+ tumor cells","volume":"14","author":"Wu","year":"2008","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.beha.2016.07.003_bib14","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1111\/bjh.12708","article-title":"Immunomodulatory agents lenalidomide and pomalidomide co-stimulate T cells by inducing degradation of T cell repressors Ikaros and Aiolos via modulation of the E3 ubiquitin ligase complex CRL4(CRBN)","volume":"164","author":"Gandhi","year":"2014","journal-title":"Br J Haematol"},{"key":"10.1016\/j.beha.2016.07.003_bib15","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1126\/science.1244851","article-title":"Lenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple myeloma cells","volume":"343","author":"Kr\u00f6nke","year":"2014","journal-title":"Science"},{"key":"10.1016\/j.beha.2016.07.003_bib16","doi-asserted-by":"crossref","first-page":"4952","DOI":"10.1200\/JCO.2007.15.3429","article-title":"Lenalidomide monotherapy in relapsed or refractory aggressive non-Hodgkin\u2019s lymphoma","volume":"26","author":"Wiernik","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.beha.2016.07.003_bib17","doi-asserted-by":"crossref","first-page":"5404","DOI":"10.1200\/JCO.2008.21.1169","article-title":"Lenalidomide oral monotherapy produces durable responses in relapsed or refractory indolent non-Hodgkin\u2019s lymphoma","volume":"27","author":"Witzig","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.beha.2016.07.003_bib18","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1093\/annonc\/mdq626","article-title":"An international phase II trial of single-agent lenalidomide for relapsed or refractory aggressive B-cell non-Hodgkin\u2019s lymphoma","volume":"22","author":"Witzig","year":"2011","journal-title":"Ann Oncol"},{"key":"10.1016\/j.beha.2016.07.003_bib19","doi-asserted-by":"crossref","first-page":"353","DOI":"10.3324\/haematol.2012.065995","article-title":"A phase II study of lenalidomide in patients with extranodal marginal zone B-cell lymphoma of the mucosa associated lymphoid tissue (MALT lymphoma)","volume":"98","author":"Kiesewetter","year":"2013","journal-title":"Haematologica"},{"key":"10.1016\/j.beha.2016.07.003_bib20","doi-asserted-by":"crossref","first-page":"1902","DOI":"10.1038\/leu.2013.95","article-title":"Oral lenalidomide with rituximab in relapsed or refractory diffuse large cell, follicular and transformed lymphoma: a phase II clinical trial","volume":"27","author":"Wang","year":"2013","journal-title":"Leukemia"},{"key":"10.1016\/j.beha.2016.07.003_bib21","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1111\/bjh.12755","article-title":"Lenalidomide plus rituximab can produce durable clinical responses in patients with relapsed or refractory, indolent non-Hodgkin lymphoma","volume":"165","author":"Tuscano","year":"2014","journal-title":"Br J Haematol"},{"key":"10.1016\/j.beha.2016.07.003_bib22","doi-asserted-by":"crossref","first-page":"3635","DOI":"10.1200\/JCO.2014.59.9258","article-title":"Randomized trial of lenalidomide alone versus lenalidomide plus rituximab in patients with recurrent follicular lymphoma: CALGB 50401 (Alliance)","volume":"33","author":"Leonard","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.beha.2016.07.003_bib23","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1016\/S1470-2045(14)70455-3","article-title":"Safety and activity of lenalidomide and rituximab in untreated indolent lymphoma: an open-label, phase 2 trial","volume":"15","author":"Fowler","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.beha.2016.07.003_bib24","doi-asserted-by":"crossref","first-page":"2487","DOI":"10.1056\/NEJMoa043445","article-title":"Bortezomib or high-dose dexamethasone for relapsed multiple myeloma","volume":"352","author":"Richardson","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.beha.2016.07.003_bib25","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1056\/NEJMoa0801479","article-title":"Bortezomib plus melphalan and prednisone for the initial treatment of multiple myeloma","volume":"359","author":"San Miguel","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.beha.2016.07.003_bib26","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1093\/annonc\/mdn656","article-title":"Bortezomib in patients with relapsed or refractory mantle cell lymphoma: updated time-to-event analyses of the multicentre phase 2 PINNACLE study","volume":"20","author":"Goy","year":"2009","journal-title":"Ann Oncol"},{"key":"10.1016\/j.beha.2016.07.003_bib27","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1056\/NEJMoa1412096","article-title":"Bortezomib-based therapy for newly diagnosed mantle-cell lymphoma","volume":"372","author":"Robak","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.beha.2016.07.003_bib28","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1634\/theoncologist.2011-0341","article-title":"Proteasome inhibition and combination therapy for non-Hodgkin\u2019s lymphoma: from bench to bedside","volume":"17","author":"Mato","year":"2012","journal-title":"Oncologist"},{"key":"10.1016\/j.beha.2016.07.003_bib29","doi-asserted-by":"crossref","first-page":"88","DOI":"10.4049\/jimmunol.171.1.88","article-title":"Inhibition of constitutive NF-\u03baB activation in mantle cell lymphoma B cells leads to induction of cell cycle arrest and apoptosis","volume":"171","author":"Pham","year":"2003","journal-title":"J Immunol"},{"key":"10.1016\/j.beha.2016.07.003_bib30","doi-asserted-by":"crossref","first-page":"4918","DOI":"10.1182\/blood-2008-08-174110","article-title":"The NF-{kappa}B negative regulator TNFAIP3 (A20) is inactivated by somatic mutations and genomic deletions in marginal zone lymphomas","volume":"113","author":"Novak","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.beha.2016.07.003_bib31","doi-asserted-by":"crossref","first-page":"738","DOI":"10.3324\/haematol.2008.001537","article-title":"A phase II study of bortezomib in patients with MALT lymphoma","volume":"94","author":"Troch","year":"2009","journal-title":"Haematologica"},{"key":"10.1016\/j.beha.2016.07.003_bib32","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.1136\/gut.52.11.1656","article-title":"Proposal for a new histological grading system for post-treatment evaluation of gastric MALT-lymphoma","volume":"52","author":"Copie-Bergman","year":"2003","journal-title":"Gut"},{"key":"10.1016\/j.beha.2016.07.003_bib33","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1093\/annonc\/mdq416","article-title":"Clinical activity of bortezomib in relapsed\/refractory MALT lymphomas: results of a phase II study of the International Extranodal Lymphoma Study Group (IELSG)","volume":"22","author":"Conconi","year":"2011","journal-title":"Ann Oncol"},{"key":"10.1016\/j.beha.2016.07.003_bib34","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1182\/blood-2009-08-233155","article-title":"Results of a phase 2 study of bortezomib in patients with relapsed or refractory indolent lymphoma","volume":"115","author":"Di Bella","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.beha.2016.07.003_bib35","doi-asserted-by":"crossref","first-page":"5023","DOI":"10.1200\/JCO.2008.17.7980","article-title":"Multicenter randomized phase II study of weekly or twice-weekly bortezomib plus rituximab in patients with relapsed or refractory follicular or marginal-zone B-cell lymphoma","volume":"27","author":"De Vos","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.beha.2016.07.003_bib36","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1002\/cncr.23236","article-title":"A phase 2 trial of fludarabine and mitoxantrone chemotherapy followed by yttrium-90 ibritumomab tiuxetan for patients with previously untreated, indolent, nonfollicular, non-Hodgkin lymphoma","volume":"112","author":"Zinzani","year":"2008","journal-title":"Cancer"},{"key":"10.1016\/j.beha.2016.07.003_bib37","doi-asserted-by":"crossref","first-page":"42","DOI":"10.3109\/10428194.2010.534519","article-title":"90Y-ibritumomab tiuxetan (Zevalin) in heavily pretreated patients with mucosa associated lymphoid tissue lymphoma","volume":"52","author":"Hoffmann","year":"2011","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.beha.2016.07.003_bib38","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1002\/hon.2078","article-title":"Efficacy of 90yttrium-ibritumomab tiuxetan in relapsed\/refractory extranodal marginal-zone lymphoma","volume":"32","author":"Vanazzi","year":"2014","journal-title":"Hematol Oncol"},{"key":"10.1016\/j.beha.2016.07.003_bib39","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1111\/bjh.13021","article-title":"90Y-ibritumomab tiuxetan radiotherapy as first-line therapy for early stage low-grade B-cell lymphomas, including bulky disease","volume":"167","author":"Samaniego","year":"2014","journal-title":"Br J Haematol"},{"key":"10.1016\/j.beha.2016.07.003_bib40","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.3109\/10428194.2014.975801","article-title":"Phase II study of 90Y ibritumomab tiuxetan (Zevalin) in patients with previously untreated marginal zone lymphoma","volume":"56","author":"Lossos","year":"2015","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.beha.2016.07.003_bib41","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1093\/annonc\/mdn692","article-title":"Prospective trial of targeted radioimmunotherapy with Y-90 ibritumomab tiuxetan (Zevalin) for front-line treatment of early-stage extranodal indolent ocular adnexal lymphoma","volume":"20","author":"Esmaeli","year":"2009","journal-title":"Ann Oncol"},{"key":"10.1016\/j.beha.2016.07.003_bib42","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1159\/000381524","article-title":"Obinutuzumab (GA101) for the treatment of chronic lymphocytic leukemia and other B-cell non-Hodgkin\u2019s lymphomas: a glycoengineered type II CD20 antibody","volume":"38","author":"Goede","year":"2015","journal-title":"Oncol Res Treat"},{"key":"10.1016\/j.beha.2016.07.003_bib43","doi-asserted-by":"crossref","first-page":"4393","DOI":"10.1182\/blood-2009-06-225979","article-title":"Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity","volume":"115","author":"M\u00f6ssner","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.beha.2016.07.003_bib44","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1158\/1535-7163.MCT-12-1182","article-title":"Preclinical activity of the type II CD20 antibody GA101 (obinutuzumab) compared with rituximab and ofatumumab in vitro and in xenograft models","volume":"12","author":"Herter","year":"2013","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.beha.2016.07.003_bib45","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1056\/NEJMoa1313984","article-title":"Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions","volume":"370","author":"Goede","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.beha.2016.07.003_bib46","doi-asserted-by":"crossref","first-page":"5118","DOI":"10.1182\/blood-2012-02-408773","article-title":"A phase 1 study of obinutuzumab induction followed by 2 years of maintenance in patients with relapsed CD20-positive B-cell malignancies","volume":"119","author":"Sehn","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.beha.2016.07.003_bib47","doi-asserted-by":"crossref","first-page":"5126","DOI":"10.1182\/blood-2012-01-404368","article-title":"Phase 1 study results of the type II glycoengineered humanized anti-CD20 monoclonal antibody obinutuzumab (GA101) in B-cell lymphoma patients","volume":"119","author":"Salles","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.beha.2016.07.003_bib48","doi-asserted-by":"crossref","first-page":"2920","DOI":"10.1200\/JCO.2012.46.9718","article-title":"Obinutuzumab (GA101) in patients with relapsed\/refractory indolent non-Hodgkin lymphoma: results from the phase II GAUGUIN study","volume":"31","author":"Salles","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.beha.2016.07.003_bib49","doi-asserted-by":"crossref","first-page":"3467","DOI":"10.1200\/JCO.2014.59.2139","article-title":"Randomized phase II trial comparing obinutuzumab (GA101) with rituximab in patients with relapsed CD20+ indolent B-cell non-Hodgkin lymphoma: final analysis of the GAUSS study","volume":"33","author":"Sehn","year":"2015","journal-title":"J Clin Oncol"},{"issue":"Suppl 18","key":"10.1016\/j.beha.2016.07.003_bib50","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2015.33.18_suppl.lba8502","article-title":"GADOLIN: primary results from a phase III study of obinutuzumab plus bendamustine compared with bendamustine alone in patients with rituximab-refractory indolent non-Hodgkin lymphoma","volume":"33","author":"Sehn","year":"2015","journal-title":"J Clin Oncol (ASCO Meeting Abstracts)"},{"key":"10.1016\/j.beha.2016.07.003_bib51","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1038\/nri955","article-title":"Regulation of B-cell fate by antigen-receptor signals","volume":"2","author":"Niiro","year":"2002","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.beha.2016.07.003_bib52","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/j.semcancer.2013.09.001","article-title":"B-cell receptor signaling as a driver of lymphoma development and evolution","volume":"23","author":"Niemann","year":"2013","journal-title":"Semin Cancer Biol"},{"key":"10.1016\/j.beha.2016.07.003_bib53","doi-asserted-by":"crossref","first-page":"13075","DOI":"10.1073\/pnas.1004594107","article-title":"The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy","volume":"107","author":"Honigberg","year":"2010","journal-title":"Proc Natl Acad Sci U. S. A"},{"key":"10.1016\/j.beha.2016.07.003_bib54","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1200\/JCO.2012.42.7906","article-title":"Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed\/refractory B-cell malignancies","volume":"31","author":"Advani","year":"2013","journal-title":"J Clin Oncol"},{"issue":"Suppl 15","key":"10.1016\/j.beha.2016.07.003_bib55","article-title":"A phase III study of ibrutinib in combination with either bendamustine and rituximab (BR) or rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP) in patients with previously treated follicular lymphoma or marginal zone lymphoma","volume":"33","author":"Fowler","year":"2015","journal-title":"J Clin Oncol (ASCO Meeting Abstracts)"},{"key":"10.1016\/j.beha.2016.07.003_bib56","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1038\/nrm3290","article-title":"PI3K signalling: the path to discovery and understanding","volume":"13","author":"Vanhaesebroeck","year":"2012","journal-title":"Nat Rev Mol Cell Biol"},{"key":"10.1016\/j.beha.2016.07.003_bib57","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1182\/blood-2010-03-275305","article-title":"CAL-101, a p110delta selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signalling and cellular viability","volume":"117","author":"Lannutti","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.beha.2016.07.003_bib58","doi-asserted-by":"crossref","first-page":"3406","DOI":"10.1182\/blood-2013-11-538546","article-title":"Idelalisib, a selective inhibitor of phosphatidylinositol 3-kinase-\u03b4, as therapy for previously treated indolent non-Hodgkin lymphoma","volume":"123","author":"Flinn","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.beha.2016.07.003_bib59","article-title":"Idelalisib monotherapy and durable responses in patients with relapsed or refractory marginal zone lymphoma (MZL)","volume":"126","author":"Martin","year":"2015","journal-title":"Blood (ASH Meeting Abstracts)"},{"key":"10.1016\/j.beha.2016.07.003_bib60","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1056\/NEJMoa1314583","article-title":"PI3K\u03b4 inhibition by idelalisib in patients with relapsed indolent lymphoma","volume":"370","author":"Gopal","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.beha.2016.07.003_bib61","article-title":"A phase 1 study of venetoclax (ABT-199\/GDC-0199) monotherapy in patients with relapsed\/refractory non-Hodgkin lymphoma","volume":"126","author":"Gerecitano","year":"2015","journal-title":"Blood (ASH Meeting Abstracts)"},{"key":"10.1016\/j.beha.2016.07.003_bib62","article-title":"Preliminary results of a phase II study of single agent BAY 80-6946, a novel PI3K inhibitor, in patients with relapsed\/refractory, indolent or aggressive lymphoma","volume":"122","author":"Dreyling","year":"2013","journal-title":"Blood (ASH meeting Abstracts)"},{"issue":"Suppl 15","key":"10.1016\/j.beha.2016.07.003_bib63","first-page":"8524","article-title":"A phase I trial of ublituximab (TG-1101), a novel glycoengineered anti-CD20 monoclonal antibody (mAb) in B-cell non-Hodgkin lymphoma patients with prior exposure to rituximab","volume":"32","author":"O'Connor","year":"2014","journal-title":"J Clin Oncol (ASCO Meeting Abstracts)"},{"issue":"Suppl 18","key":"10.1016\/j.beha.2016.07.003_bib64","first-page":"8548","article-title":"Ublituximab plus TGR-1202 activity and safety profile in relapsed\/refractory B-cell NHL and high-risk CLL","volume":"33","author":"Lunning","year":"2015","journal-title":"J Clin Oncol (ASCO Meeting Abstracts)"},{"issue":"Suppl 18","key":"10.1016\/j.beha.2016.07.003_bib65","first-page":"8501","article-title":"Safety and activity of the chemotherapy-free triplet of ublituximab, TGR-1202, and ibrutinib in relapsed B-cell malignancies","volume":"33","author":"Fowler","year":"2015","journal-title":"J Clin Oncol (ASCO Meeting Abstracts)"}],"container-title":["Best Practice & Research Clinical Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521692616300780?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521692616300780?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,12]],"date-time":"2025-06-12T00:06:57Z","timestamp":1749686817000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521692616300780"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,3]]},"references-count":65,"journal-issue":{"issue":"1-2","published-print":{"date-parts":[[2017,3]]}},"alternative-id":["S1521692616300780"],"URL":"https:\/\/doi.org\/10.1016\/j.beha.2016.07.003","relation":{},"ISSN":["1521-6926"],"issn-type":[{"type":"print","value":"1521-6926"}],"subject":[],"published":{"date-parts":[[2017,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Possible novel agents in marginal zone lymphoma","name":"articletitle","label":"Article Title"},{"value":"Best Practice & Research Clinical Haematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.beha.2016.07.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}